BALTIMORE, Apr. 15, 2015 /PRNewswire/ --Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new research update on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com.
In the update, analyst Rob Goldman discusses how a recent diabetes development breakthrough sets the stage for the Company's first human clinical trials for diabetes.
"A member of PMCB's international Diabetes Consortium, who, along with her team, developed a new, insulin-producing cell line from human liver cells (Melligen), published an article in the scientific journal Molecular Therapy illustrating that tests on diabetic mice with transplanted Melligen cells demonstrated an ability to reverse Type 1 diabetes (T1D). The article noted that in order for the cells to be effective in treating humans with T1D, they must be protected from the body's immune system after introduction. The next step is to engage in vivo studies using Cell-in-a-Box® to confirm the Melligen line's viability after encapsulation, as well as other parameters related to its insulin production. Once confirmed, the next stage would be to initiate Phase I human clinical trials."
Goldman points out, "This recent study notes that the Melligen cell line, when combined with encapsulation, has clear advantages over current insulin injection and pump therapies for Type 1 diabetes. Therefore, the PMCB delivery system approach could potentially replace these therapies. According to Diabetes.org, $176 billion is spent annually in the U.S. on direct costs attributable to diagnosed diabetes and 1 in 10 health care dollars is spent treating diabetes and its complications. And, diabetes kills more Americans than AIDS and breast cancer combined.
"Plus, given the diabetes market size, once the next study is completed and a Phase I trial protocol design is underway, PMCB stock could enjoy a significant valuation increase, as the technology's effectiveness and flexibility would take center stage."
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was recently compensated by a third party in the amount of $4000 for investment research services and has been compensated $3500 for the publication of a series of articles.
About PharmaCyte Biotech: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE Goldman Small Cap Research